2012/11/17 by L. A. Black, Andrew J. McLachlan, Joanna E. Griffith +4 · 1 citation
Agricultural and Biological Sciences · Chemistry · Immunology and Microbiology · Medicine · #Antibiotics #Autoimmune Bullous Skin Diseases #Biology #Chemistry #Chloramphenicol #Internal medicine #Medicine #Microbiology #Pharmacokinetics #Pharmacology #Plant and fungal interactions #Regimen #Reproductive tract infections research
paper · doi:10.1111/jvp.12024
openalex publication_date 2012/11/17 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/15
Clinically normal koalas (n = 19) received a single dose of intravenous (i.v.) chloramphenicol sodium succinate (SS) (25 mg/kg; n = 6), subcutaneous (s.c.) chloramphenicol SS (60 mg/kg; n = 7) or s.c. chloramphenicol base (60 mg/kg; n = 6). Serial plasma samples were collected over 24-48 h, and chloramphenicol concentrations were determined using a validated high-performance liquid chromatography assay. The median (range) apparent clearance (CL/F) and elimination half-life (t(1/2)) of chloramphenicol after i.v. chloramphenicol SS administration were 0.52 (0.35-0.99) L/h/kg and 1.13 (0.76-1.40) h, respectively. Although the area under the concentration-time curve was comparable for the two s.c. formulations, the absorption rate-limited disposition of chloramphenicol base resulted in a lower median C(max) (2.52; range 0.75-6.80 μg/mL) and longer median tmax (8.00; range 4.00-12.00 h) than chloramphenicol SS (C(max) 20.37, range 13.88-25.15 μg/mL; t(max) 1.25, range 1.00-2.00 h). When these results were compared with susceptibility data for human Chlamydia isolates, the expected efficacy of the current chloramphenicol dosing regimen used in koalas to treat chlamydiosis remains uncertain and at odds with clinical observations.